References
- Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation110, 1042–1046 (2004).
- Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J.27, 849–953 (2006).
- Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart86, 516–521 (2001).
- Hobbs FD, Fitzmaurice DA, Mant J et al. A randomized controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol. Assess.9, 1–74 (2005).
- Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba follow-up study. Am. J. Med.98, 476–484 (1995).
- Stewart S, Murphy N, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart90, 286–292 (2004).
- Le Heuzey JY, Paziaud O, Piot O et al. Cost of Care Distribution in Atrial Fibrillation Patients: the COCAF study. Am. Heart J.147, 121–126 (2004).
- Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med.158, 229–234 (1998).
- Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systemic review of randomized controlled trials. Arch. Intern. Med.166, 719–728 (2006).
- Wyse DG, Waldo AL, DiMarco JP et al.; AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med.347, 1825–1833 (2002).
- Roy D, Talajic M, Nattel S et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med.358, 2667–2677 (2008).
- Corley SD, Epstein AE, DiMarco JP et al.; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation109, 1509–1513 (2004).
- Singh BN, Connolly SJ, Crijns HJ et al.; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med.357, 887–999 (2007).
- Davy JM, Herold M, Hoglund C et al.; ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study. Am. Heart J.156, 527.e1–e9 (2008).
- Hohnloser SH, Crijns HJ, van Eickels M et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med.360, 668–678 (2009).
- LE Heuzey JY, DE Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A Short-Term, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol.21(6), 597–605 (2010).
- Kober L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med.358, 2678–2687 (2008).
- Packer DL, Prutkin JM, Hellkamp AS et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation120, 2170–2176 (2009).
Website
- NICE. Atrial fibrillation – dronedarone: appraisal consultation document 2 (Accessed 8 May 2010)